Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 509

1.

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.

Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J.

Br J Haematol. 2005 Jun;129(6):776-83.

PMID:
15953004
2.

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.

Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG.

Br J Haematol. 2010 Feb;148(4):562-8. doi: 10.1111/j.1365-2141.2009.07981.x. Epub 2009 Nov 16.

PMID:
19919652
3.

Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.

Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A, Crowley J, Vescio R.

Br J Haematol. 2009 Sep;146(6):619-26. doi: 10.1111/j.1365-2141.2009.07803.x. Epub 2009 Jul 20.

PMID:
19622094
4.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

5.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

6.

Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.

Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z.

Leuk Res. 2009 Dec;33(12):1615-8. doi: 10.1016/j.leukres.2009.04.006.

PMID:
19773080
7.

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD.

Br J Haematol. 2005 Jun;129(6):755-62.

PMID:
15953001
8.

Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.

Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J.

Br J Haematol. 2009 Mar;144(6):887-94. doi: 10.1111/j.1365-2141.2008.07572.x. Epub 2009 Jan 12.

PMID:
19183191
9.

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.

Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.

Cancer. 2010 Jul 1;116(13):3143-51. doi: 10.1002/cncr.25143.

10.

A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.

Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS; Korean Multiple Myeloma Working Party.

Int J Hematol. 2006 May;83(4):309-13.

PMID:
16757429
11.

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.

Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK.

Br J Haematol. 2009 Jan;144(2):169-75. doi: 10.1111/j.1365-2141.2008.07409.x. Epub 2008 Nov 19.

PMID:
19036114
12.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ.

Biol Blood Marrow Transplant. 2012 Mar;18(3):486-92. doi: 10.1016/j.bbmt.2011.12.580. Epub 2011 Dec 22.

13.

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.

J Clin Oncol. 2006 Feb 20;24(6):937-44. Epub 2006 Jan 17.

14.

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.

J Clin Oncol. 2009 Jul 20;27(21):3518-25. doi: 10.1200/JCO.2008.18.3087. Epub 2009 Jun 15.

15.

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J.

J Clin Oncol. 2007 Oct 1;25(28):4452-8. Epub 2007 Sep 4.

16.

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.

Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS.

J Clin Oncol. 2009 Oct 20;27(30):5015-22. doi: 10.1200/JCO.2008.19.5370. Epub 2009 Sep 8.

17.

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.

Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, Walters IB, Noga SJ.

Am J Hematol. 2009 Oct;84(10):657-60. doi: 10.1002/ajh.21517.

18.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC.

Br J Haematol. 2004 Oct;127(2):165-72.

PMID:
15461622
19.
20.

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.

Lü S, Wang J, Xu X, Ni X, Huang C, Qiu H, Hu X, Yang J.

Int J Hematol. 2009 Jan;89(1):34-8. doi: 10.1007/s12185-008-0218-9. Epub 2008 Dec 13.

PMID:
19082817
Items per page

Supplemental Content

Write to the Help Desk